ModernGraham Valuation

Company Name:

Company Ticker SPPI Date of Analysis

Spectrum Pharmaceuticals, Inc.



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

8/11/2018

Defensive Inv of the following 7

Defensive Investor; m	ust pass 6 out of the following 7 tests.					
	1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$2,345,273,926 Pass			
	2. Sufficiently Strong Financial Condition	Current Ratio > 2	2.97 Pass			
	3. Earnings Stability	Positive EPS for 10 years prior	Fail			
	4. Dividend Record	Dividend Payments for 10 years prior	Fail			
		Increase of 33% in EPS in past 10 years using 3 year averages at				
	5. Earnings Growth	beginning and end	438.60% Pass			
	6. Moderate PEmg Ratio	PEmg < 20	-22.67 Fail			
	7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	6.90 Fail			
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.						
	1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	2.97 Pass			
	2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	0.00 Pass			
	3. Earnings Stability	Positive EPS for 5 years prior	Fail			
	4. Dividend Record	Currently Pays Dividend	Fail			
	5. Earnings Growth	EPSmg greater than 5 years ago	Fail			
		Score				
Suitability						
	Defensive	No				
	Enterprising	No				
Stage 2: Deter	mination of Intrinsic Value					
	EPSmg	-\$0.98				
	MG Growth Estimate	-4.25%				
	MG Value	\$1.56				
	MG Value based on 3% Growth	-\$14.20				
	MG Value based on 0% Growth	-\$8.32				
	Market Implied Growth Rate	-15.58%				
MG Opinion						
	Current Price	\$22.20				
	% of Intrinsic Value	1425.02%				
	Opinion	Overvalued				
	MG Grade	D				

Stage 3: Information for Further Research


Net Current Asset Value (NCAV)	\$1.56
Graham Number	\$0.00
PEmg	-22.67
Current Ratio	2.97
PB Ratio	6.90
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0

Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus

Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	-\$1.04	Next Fiscal Year Estimate	-\$0.98
Dec2017	-\$1.07	Dec2017	-\$0.94
Dec2016	-\$0.96	Dec2016	-\$0.72
Dec2015	-\$0.81	Dec2015	-\$0.4
Dec2014	-\$0.71	Dec2014	-\$0.17
Dec2013	-\$1.02	Dec2013	\$0.06
Dec2012	\$1.46	Dec2012	\$0.43
Dec2011	\$0.86	Dec2011	-\$0.20
Dec2010	-\$0.95	Dec2010	-\$0.7
Dec2009	-\$0.48	Dec2009	-\$0.7
Dec2008	-\$0.45	Dec2008	-\$0.8
Dec2007	-\$1.17	Dec2007	-\$1.3
Dec2006	-\$0.96	Dec2006	-\$2.27
Dec2005	-\$1.06	Dec2005	-\$5.66
Dec2004	-\$0.98	Dec2004	-\$16.23
Dec2003	-\$4.83	Dec2003	-\$32.90
Dec2002	-\$12.34	Dec2002	-\$51.41
Dec2001	-\$36.50	Balance Sheet Information	3/1/2018
Dec2000	-\$109.25	Total Current Assets	\$277,028,000
Dec1999	-\$92.00	Total Current Liabilities	\$93,422,000
Dec1998	-\$51.75	Long-Term Debt	\$0
		Total Assets	\$444,273,000
		Intangible Assets	\$148,546,000
		Total Liabilities	\$119,979,000
		Shares Outstanding (Diluted Average)	100,810,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company Spectrum Pharmaceuticals Inc Valuation – Initial Coverage \$SPPI

Other ModernGraham posts about related companies

Akorn Inc Valuation – July 2018 \$AKRX Mallinckrodt PLC Valuation – July 2018 \$MNK Bristol-Myers Squibb Company Valuation – June 2018 \$BMY Biogen Inc Valuation – June 2018 \$BIIB Mylan NV Valuation – June 2018 \$MYL Amgen Inc Valuation – June 2018 \$AMGN Celgene Corp Valuation – June 2018 \$CELG Allergan PLC Valuation – May 2018 \$AGN Incyte Corp Valuation – April 2018 \$INCY Regeneron Pharmaceuticals Inc Valuation – April 2018 \$REGN